Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company") today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC ("Boltz"), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and warrant further computational analysis and experimental validation.

Completion of this stage moves the initiative, announced in June 2026, from launch to an initial assessment of screening predictions. The predictions have not been experimentally validated and serve only as a starting point for evaluating potential follow-up research within MitoCareX’s small-molecule discovery programs.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.